Neonatal lupus erythrematosus overview: Difference between revisions
Jump to navigation
Jump to search
Mahmoud Sakr (talk | contribs) No edit summary |
Mahmoud Sakr (talk | contribs) No edit summary |
||
| Line 12: | Line 12: | ||
==Epidemiology and Demographics== | ==Epidemiology and Demographics== | ||
==Screening== | |||
==Natural History, Complications and Prognosis== | ==Natural History, Complications and Prognosis== | ||
Revision as of 21:29, 23 August 2013
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Mahmoud Sakr, M.D. [2]
Overview
Neonatal lupus erythrematosus is an autoimmune disease that results from passive transfer of autoantibodies from the mother to the fetus. It occurs in about 1 to 2 percent of babies born to mothers with autoimmune disease, primarily systemic lupus erythematosus and Sjögren’s syndrome, and antibodies to SSA/Ro and/or SSB/La.[1][2].
Pathophysiology
Differentiating Pericarditis from other Diseases
Epidemiology and Demographics
Screening
Natural History, Complications and Prognosis
Diagnosis
History and Symptoms
Physical Examination
Laboratory Findings
EKG
Echocardiography
Treatment
Medical Therapy
Surgery
References
- ↑ Brucato A, Cimaz R, Caporali R, Ramoni V, Buyon J (2011). "Pregnancy outcomes in patients with autoimmune diseases and anti-Ro/SSA antibodies". Clin Rev Allergy Immunol. 40 (1): 27–41. doi:10.1007/s12016-009-8190-6. PMC 3558034. PMID 20012231.
- ↑ Buyon JP (2009). "Updates on lupus and pregnancy". Bull NYU Hosp Jt Dis. 67 (3): 271–5. PMID 19852749.